title: Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock.
abstract: Immune complexes containing human gamma (g)1 or murine g2a antibodies generate secondary effector mechanisms via Fc receptor binding or complement activation, whereas those containing human g4 or murine g1 antibodies generally do not. Therefore, isotype selection of therapeutic antibodies may have important clinical consequences. In a rabbit model of human tumor necrosis factor (rhuTNF)-induced pyrexia, a murine/human chimeric g4 anti-human TNF-alpha monoclonal antibody (mAb) (cCB0011) showed a dose-dependent inhibition of pyrexia, whereas a g1 isotype variant of the same mAb gave a marked pyrexia that was seen at all doses indicative of an immune complex-mediated response. To investigate whether isotype difference could influence mAb efficacy in pathological disease states, hamster/murine chimeric g1 and g2a anti-murine TNF-alpha mAbs (TN3g1, TN3g2a) were studied in experimental shock in mice and rats. In lipopolysaccharide-induced shock in mice, treatment with TN3g1 mAb at 30 and 3 mg/kg resulted in 90% survival by 72 h (p < or = 0.004), and prolonged survival to 45 h (p < or = 0.05), respectively, compared with 100% mortality by 27 h in controls. In contrast, a g2a isotype variant of the same mAb (30 mg/kg) resulted in only 10% survival by 72 h (p < or = 0.05). In a neutropenic sepsis model in rats there was greater survival in animals receiving the g1 isotype of TN3 compared with g2a isotype variant (70 vs. 27%; p < or = 0.005) with 100% mortality in the controls. These differences were not due to the pharmacokinetic profiles of the mAbs. In models of experimental shock antibody isotype can affect outcome with inactive isotypes (human g4 and murine g1) being more efficacious than active isotypes (human g1 and murine g2a).
authors.affiliation: Celltech, Slough, Berkshire, United Kingdom.
authors.forename: A J
authors.initials: AJ
authors.lastname: Suitters
authors.forename: R
authors.initials: R
authors.lastname: Foulkes
authors.forename: S M
authors.initials: SM
authors.lastname: Opal
authors.forename: J E
authors.initials: JE
authors.lastname: Palardy
authors.forename: J S
authors.initials: JS
authors.lastname: Emtage
authors.forename: M
authors.initials: M
authors.lastname: Rolfe
authors.forename: S
authors.initials: S
authors.lastname: Stephens
authors.forename: A
authors.initials: A
authors.lastname: Morgan
authors.forename: A R
authors.initials: AR
authors.lastname: Holt
authors.forename: L C
authors.initials: LC
authors.lastname: Chaplin
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000627:therapeutic use*; D005334:Fever / Q000139:chemically induced / Q000628:therapy*; D006801:Humans; D007132:Immunoglobulin Isotypes / Q000627:therapeutic use / Q000633:toxicity*; D008070:Lipopolysaccharides / Q000633:toxicity; D008297:Male; D051379:Mice; D011817:Rabbits; D011993:Recombinant Fusion Proteins / Q000493:pharmacokinetics / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000633:toxicity; D012772:Shock, Septic / Q000139:chemically induced / Q000276:immunology / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology* / Q000633:toxicity*
chemical_list: D000911:Antibodies, Monoclonal; D007132:Immunoglobulin Isotypes; D008070:Lipopolysaccharides; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha